Efficacy and safety of efalizumab in a large cohort of patients with moderate to severe plaque psoriasis: pooled results from randomized phase III trials

Kenneth Gordon; David Pariser; Richard Langley; Ivor Caro

doi:10.1016/j.jaad.2003.10.010

Efficacy and safety of efalizumab in a large cohort of patients with moderate to severe plaque psoriasis: pooled results from randomized phase III trials

Journal of the American Academy of Dermatology ◽

10.1016/j.jaad.2003.10.010 ◽

2004 ◽

Vol 50 (3) ◽

pp. P1 ◽

Cited By ~ 5

Author(s):

Kenneth Gordon ◽

David Pariser ◽

Richard Langley ◽

Ivor Caro

Keyword(s):

Plaque Psoriasis ◽

Large Cohort ◽

Phase Iii ◽

Efficacy And Safety ◽

Severe Plaque Psoriasis ◽

Phase Iii Trials

Download Full-text

Efficacy and safety of secukinumab by age group in patients with moderate-to-severe plaque psoriasis: Pooled analysis of 4 phase III trials

Journal of the American Academy of Dermatology ◽

10.1016/j.jaad.2016.02.965 ◽

2016 ◽

Vol 74 (5) ◽

pp. AB247

Keyword(s):

Plaque Psoriasis ◽

Pooled Analysis ◽

Phase Iii ◽

Age Group ◽

Efficacy And Safety ◽

Severe Plaque Psoriasis ◽

Phase Iii Trials

Download Full-text

Efficacy and Safety of HLX03, an Adalimumab Biosimilar, in Patients with Moderate-to-Severe Plaque Psoriasis: A Randomized, Double-Blind, Phase III Study

Advances in Therapy ◽

10.1007/s12325-021-01899-0 ◽

2021 ◽

Author(s):

Lin Cai ◽

Linfeng Li ◽

Hao Cheng ◽

Yangfeng Ding ◽

Zhenshu Biao ◽

...

Keyword(s):

Plaque Psoriasis ◽

Phase Iii ◽

Efficacy And Safety ◽

Double Blind ◽

Severe Plaque Psoriasis ◽

Phase Iii Study

Download Full-text

Efficacy and Safety of Secukinumab in Elderly Subjects with Moderate to Severe Plaque Psoriasis: A Pooled Analysis of Phase III Studies

Drugs & Aging ◽

10.1007/s40266-018-0520-z ◽

2018 ◽

Vol 35 (2) ◽

pp. 135-144 ◽

Cited By ~ 23

Author(s):

Andreas Körber ◽

Charis Papavassilis ◽

Vaishali Bhosekar ◽

Maximilian Reinhardt

Keyword(s):

Plaque Psoriasis ◽

Pooled Analysis ◽

Phase Iii ◽

Elderly Subjects ◽

Efficacy And Safety ◽

Severe Plaque Psoriasis ◽

Phase Iii Studies

Download Full-text

Correction to: Efficacy and Safety of Switching to Ixekizumab in Etanercept Non-Responders: A Subanalysis from Two Phase III Randomized Clinical Trials in Moderate-to-Severe Plaque Psoriasis (UNCOVER-2 and -3)

American Journal of Clinical Dermatology ◽

10.1007/s40257-018-0353-x ◽

2018 ◽

Vol 19 (3) ◽

pp. 457-457 ◽

Cited By ~ 1

Author(s):

Andrew Blauvelt ◽

Kim A. Papp ◽

Christopher E. M. Griffiths ◽

Luis Puig ◽

Jamie Weisman ◽

...

Keyword(s):

Clinical Trials ◽

Plaque Psoriasis ◽

Randomized Clinical Trials ◽

Phase Iii ◽

Efficacy And Safety ◽

Two Phase ◽

Severe Plaque Psoriasis

Download Full-text

Efficacy and safety of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with moderate‐to‐severe plaque psoriasis over 52 weeks: a phase III, randomized controlled trial (ESTEEM 2)

British Journal of Dermatology ◽

10.1111/bjd.14164 ◽

2015 ◽

Vol 173 (6) ◽

pp. 1387-1399 ◽

Cited By ~ 201

Author(s):

C. Paul ◽

J. Cather ◽

M. Gooderham ◽

Y. Poulin ◽

U. Mrowietz ◽

...

Keyword(s):

Randomized Controlled Trial ◽

Plaque Psoriasis ◽

Controlled Trial ◽

Phase Iii ◽

Efficacy And Safety ◽

Severe Plaque Psoriasis ◽

Phosphodiesterase 4 ◽

Randomized Controlled ◽

Phosphodiesterase 4 Inhibitor

Download Full-text

Tofacitinib improves pruritus and health-related quality of life up to 52 weeks: Results from 2 randomized phase III trials in patients with moderate to severe plaque psoriasis

Journal of the American Academy of Dermatology ◽

10.1016/j.jaad.2016.07.040 ◽

2016 ◽

Vol 75 (6) ◽

pp. 1162-1170.e3 ◽

Cited By ~ 29

Author(s):

Steven R. Feldman ◽

Diamant Thaçi ◽

Melinda Gooderham ◽

Matthias Augustin ◽

Claudia de la Cruz ◽

...

Keyword(s):

Quality Of Life ◽

Plaque Psoriasis ◽

Phase Iii ◽

Health Related Quality ◽

Severe Plaque Psoriasis ◽

Related Quality ◽

Phase Iii Trials ◽

Health Related

Download Full-text

Impact of efalizumab on patient-reported outcomes in patients with moderate to severe plaque psoriasis: pooled results from three randomized phase III trials

Journal of the American Academy of Dermatology ◽

10.1016/j.jaad.2003.10.549 ◽

2004 ◽

Vol 50 (3) ◽

pp. P156

Author(s):

Alan Menter ◽

Tiffani Hamilton ◽

Ivor Caro ◽

Amy Chen-Rundle

Keyword(s):

Plaque Psoriasis ◽

Patient Reported Outcomes ◽

Phase Iii ◽

Severe Plaque Psoriasis ◽

Patient Reported ◽

Phase Iii Trials

Download Full-text

Treating Moderate-to-Severe Plaque Psoriasis With Guselkumab: A Review of Phase II and Phase III Trials

Annals of Pharmacotherapy ◽

10.1177/1060028017743268 ◽

2017 ◽

Vol 52 (4) ◽

pp. 380-387 ◽

Cited By ~ 5

Author(s):

Seth T. Howell ◽

Leah A. Cardwell ◽

Steven R. Feldman

Keyword(s):

Phase Ii ◽

Plaque Psoriasis ◽

Phase Iii ◽

Severe Plaque Psoriasis ◽

Phase Iii Trials

Download Full-text

Efficacy and safety of continuous every-2-week dosing of ixekizumab over 52 weeks in patients with moderate-to-severe plaque psoriasis in a randomized phase III trial (IXORA-P)

British Journal of Dermatology ◽

10.1111/bjd.16426 ◽

2018 ◽

Vol 178 (6) ◽

pp. 1315-1323 ◽

Cited By ~ 23

Author(s):

R.G. Langley ◽

K. Papp ◽

M. Gooderham ◽

L. Zhang ◽

C. Mallinckrodt ◽

...

Keyword(s):

Plaque Psoriasis ◽

Phase Iii ◽

Efficacy And Safety ◽

Phase Iii Trial ◽

Severe Plaque Psoriasis

Download Full-text

A phase III open-label, randomized multicenter study to evaluate efficacy and safety of secukinumab in pediatric patients with moderate to severe plaque psoriasis: 24-week results

Journal of the American Academy of Dermatology ◽

10.1016/j.jaad.2021.08.066 ◽

2021 ◽

Author(s):

Nina Magnolo ◽

Külli Kingo ◽

Vivian Laquer ◽

John Browning ◽

Adam Reich ◽

...

Keyword(s):

Multicenter Study ◽

Plaque Psoriasis ◽

Pediatric Patients ◽

Phase Iii ◽

Efficacy And Safety ◽

Open Label ◽

Severe Plaque Psoriasis

Download Full-text